<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05102669</url>
  </required_header>
  <id_info>
    <org_study_id>RIS-COV</org_study_id>
    <nct_id>NCT05102669</nct_id>
  </id_info>
  <brief_title>Spike-specific Cellular Immune Response After COVID-19 Vaccination</brief_title>
  <acronym>RIS-COV</acronym>
  <official_title>Spike-specific Cellular Immune Response After COVID-19 Vaccination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS San Raffaele Roma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS San Raffaele Roma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this study is to evaluate whether COVID-19 vaccination induces a persistent cellular&#xD;
      immune response.&#xD;
&#xD;
      To this aim, blood samples are taken from vaccinated individuals and not immunized subjects&#xD;
      as a control group.&#xD;
&#xD;
      Cells isolated from blood samples are tested in vitro to assess the percentage of&#xD;
      spike-specific T and B lymphocytes 1 and 7 months after a second dose of Comirnaty vaccine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After providing written informed consent, 28 vaccinated and 25 non vaccinated subjects were&#xD;
      included in the study. All subjects were enrolled among healthcare workers in the Research&#xD;
      Centre of IRCCS San Raffaele Roma in Rome.&#xD;
&#xD;
      All the subjects declared that they never tested positive for COVID19. Blood and serum&#xD;
      samples were drowned twice from vaccinated subjects: 1 and 7 months after a second dose of&#xD;
      vaccine to evaluate T and B response to vaccine; blood was drowned once in not vaccinated&#xD;
      subjects.&#xD;
&#xD;
      Cells were collected form peripheral blood samples, while anti-S1 IgG titre was assessed in&#xD;
      serum.&#xD;
&#xD;
      Flow-cytometry was used to assess the percentage of circulating spike-specific T and B&#xD;
      lymphocytes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 12, 2021</start_date>
  <completion_date type="Actual">October 11, 2021</completion_date>
  <primary_completion_date type="Actual">October 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>measurement of cellular response</measure>
    <time_frame>7 months</time_frame>
    <description>evaluation of the increase of Spike-specific B and T cells percentage after COVID-19 vaccination</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">53</enrollment>
  <condition>COVID19</condition>
  <condition>Vaccination</condition>
  <condition>Immune Response</condition>
  <arm_group>
    <arm_group_label>vaccinated</arm_group_label>
    <description>COVID19 vaccinated subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non vaccinated</arm_group_label>
    <description>COVID19 non vaccinated subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>analysis of immunological response</intervention_name>
    <description>collection and analysis of SARS-CoV2 Spike specific blood cells</description>
    <arm_group_label>non vaccinated</arm_group_label>
    <arm_group_label>vaccinated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>analysis of serum antibodies</intervention_name>
    <description>analysis of anti-SARS-CoV2 Spike specific antibodies</description>
    <arm_group_label>vaccinated</arm_group_label>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood samples and serum samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        IRCCS San Raffaele Roma health care workers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  vaccinated and non vaccinated subjects&#xD;
&#xD;
          -  subjects that never tested positive for COVID19&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  subjects that tested positive for COVID-19&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Vitiello, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS San Raffaele Roma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IRCCS San Raffaele Roma</name>
      <address>
        <city>Roma</city>
        <zip>00163</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele Roma</investigator_affiliation>
    <investigator_full_name>Laura Vitiello, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

